About PDS Biotechnology PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal ...

A Philadelphia entrepreneur developing eye repair tech stood out among international contenders as it gears up to raise a ...

Shift Bioscience, a Cambridge-based biotech company using an AI powered virtual cell to fight age-driven diseases, has ...

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

Bio-Gene Technology Limited announced its participation in the NWR Virtual Healthcare Conference 2025, where CEO Tim Grogan will present the company’s advancements in bio-insecticides.

“The use of a ‘virtual human twin’ for medical research ... Skourides underlined that the Cypriot nano-biotechnology company EPOS – IASIS, for example, recently participated in a cutting ...

To register for the showcase, click here. Please contact your A.G.P. representative to schedule a one-on-one investor meeting with the PDS Biotech leadership team. Following the event, an archived ...

2:00 p.m. – 2:30 p.m. ET: Fireside Chat 5:00 p.m. – 6:00 p.m. ET: Panel Presentation: Development Stage Companies – Where Do Royalty and Tech Platform Plays Fit? To register for the ...

Fortress Biotech, Inc. ("Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity ...